(AOF) – The Aton group, listed under its former name of Hybrigenics, announces that as of December 31, 2023, its cash and cash equivalents amounted to 2.1 million euros, compared to 1.5 million euros. euros at the end of 2022. “This amount represents a cash flow horizon of five months for the entire group”, adds the holding specialist in health, specifying that “due to the overall economic conditions unfavorable to the sector having an unfavorable impact on the figure business and treasury”, she “took the responsible decision to postpone the performance objectives planned for 2025”.
This concerns in particular the objective of 60 million turnover, the postponement of which “will allow the company to better adapt to current challenges”.
In 2024, the Aton Group aims for “growth in its activity, however less sustained than the expected level and which should not allow the achievement of operational balance” due to “maintaining a certain number of investments at the within the subsidiaries”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.